act biotech
Eddingpharm Acquires Small Molecule Drug Assets From ACT Biotech
Eddingpharm has signed an asset purchase agreement with ACT Biotech to acquire worldwide rights to its three small molecule drug assets Telatinib, ACTB1003 and ACTB1010.



